In this study, we investigated whether IL-30 indeed has an immunosuppressive function and whether it can be leveraged in an immune therapeutic regimen for PBC, by treating model mice with murine IL-30-expressing recombinant adeno-associated virus (AAV-mIL-30). Here, IL27 is linked to primary biliary cholangitis.